Epigenetics in systemic lupus erythematosus: Leading the way for specific therapeutic agents

International Journal of Clinical Rheumatology

Volumn 6, Issue 4, 2011, Pages 423-438

  Jeffries, Matlock A ^a,b   Sawalha, Amr H ^a,b,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

DNA methylation; epigenetics; histone modification; lupus; miRNA; SLE; T cells

Indexed keywords

AUTOANTIBODY; CD40 LIGAND; CD5 ANTIGEN; CD70 ANTIGEN; CORTICOSTEROID; DNA METHYLTRANSFERASE 1; DOUBLE STRANDED DNA ANTIBODY; EFALIZUMAB; GENOMIC DNA; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 6; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MICRORNA; MICRORNA 126; MICRORNA 148A; MICRORNA 21; PERFORIN; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

AGING; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; APOPTOSIS; B LYMPHOCYTE ACTIVATION; CELL BASED GENE THERAPY; DIET RESTRICTION; DNA METHYLATION; DNA SEQUENCE; ENDOGENOUS RETROVIRUS; EPIGENETICS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HISTONE ACETYLATION; HUMAN; IMMUNE RESPONSE GENE; IMMUNOGENETICS; IMMUNOREACTIVITY; KIR2DL4 GENE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOLECULAR PATHOLOGY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS; RADIATION EXPOSURE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; ULTRAVIOLET RADIATION; VIRUS REACTIVATION;

EID: 80051973863     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.11.32     Document Type: Review

References (144)

1. Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: Clues from genetic and cytokine studies. Clin. Rev. Allergy Immunol. 40(1), 42-49 (2011).
2. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus 15(5), 308-318 (2006).
3. Sarzi-Puttini P, Atzeni F, Iaccarino L, Doria A. Environment and systemic lupus erythematosus: An overview. Autoimmunity 38(7), 465-472 (2005).
4. Javierre BM, Fernandez AF, Richter J et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 20(2), 170-179 (2010).
5. Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, Phase 3 trial. Lancet 377(9767), 721-731 (2011).
6. Lister R, Pelizzola M, Dowen RH et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271), 315-322 (2009).
7. Hughes T, Webb R, Fei Y, Wren JD, Sawalha AH. DNA methylome in human CD4+ T cells identifies transcriptionally repressive and non-repressive methylation peaks. Genes Immun. 11(7), 554-560 (2010).
8. Watson JA, Watson CJ, McCrohan A-M et al. Generation of an epigenetic signature by chronic hypoxia in prostate cells. Hum. Mol. Genet. 18(19), 3594-3604 (2009).
9. Chen P, Jiang T, Ouyang J, Cui Y, Chen Y. Epigenetic programming of diverse glucocorticoid response and inflammatory/immune-mediated disease. Med. Hypotheses. 73(5), 657-658 (2009).
10. Blazkova J, Trejbalova K, Gondois-Rey F et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 5(8), e1000554 (2009).
11. Blasi F, Toniolo D. DNA methylation and X-chromosome inactivation. Mol. Biol. Med. 1(2), 271-274 (1983).
12. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv. Cancer Res. 72, 141-196 (1998).
13. Richardson B. Effect of an inhibitor of DNA methylation on T cells. II. 5-azacytidine induces self-reactivity in antigen-specific T4+ cells. Hum. Immunol. 17(4), 456-470 (1986).
14. Quddus J, Johnson KJ, Gavalchin J et al. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J. Clin. Invest. 92(1), 38-53 (1993).
15. Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC. Mechanism of drug-induced lupus I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J. Immunol. 154(6), 3025-3035 (1995).
16. Yung RL, Richardson BC. Drug-induced lupus. Rheum. Dis. Clin. North Am. 20(1), 61-86 (1994).
17. Lee BH, Yegnasubramanian S, Lin X, Nelson WG. Procainamide is a specific inhibitor of DNA methyltransferase 1. J. Biol. Chem. 280(49), 40749-40756. (2005).
18. Scheinbart LS, Johnson MA, Gross LA, Edelstein SR, Richardson BC. Procainamide inhibits DNA methyltransferase in a human T cell line. J. Rheumatol. 18(4), 530-534 (1991).
19. Gorelik G, Fang JY, Wu A, Sawalha AH, Richardson B. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced Lupus. J. Immunol. 179(8), 5553-5563 (2007).
20. Sawalha AH, Jeffries M. Defective DNA methylation and CD70 overexpression in CD4+ T cells in MRL/lpr lupus-prone mice. Eur. J. Immunol. 37(5), 1407-1413 (2007).
21. Sawalha AH, Jeffries M, Webb R et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun. 9(4), 368-378. (2008).
22. Deng C, Kaplan MJ, Yang J et al. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum. 44(2), 397-407 (2001).
23. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 33(11), 1665-1673 (1990).
24. Kalden JR. Defective phagocytosis of apoptotic cells: Possible explanation for the induction of autoantibodies in SLE. Lupus 6(3), 326-327 (1997).
25. Gaipl US, Kuhn A, Sheriff A et al. Clearance of apoptotic cells in human SLE. Curr. Dir. Autoimmun. 9, 173-187 (2006).
26. Sano H, Takai O, Harata N, Yoshinaga K, Kodama-Kamada I, Sasaki T. Binding properties of human anti-DNA antibodies to cloned human DNA fragments. Scand. J. Immunol. 30(1), 51-63 (1989).
27. Qiao B, Wu J, Chu YW et al. Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA. Rheumatology (Oxford) 44(9), 1108-1114 (2005).
28. Wen ZK, Xu W, Xu L et al. DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-non-susceptible mice. Rheumatology (Oxford) 46(12), 1796-1803 (2007).
29. Yasuda K, Richez C, Uccellini MB et al. Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. J. Immunol. 183(5), 3109-3117 (2009).
30. Reefman E, Kuiper H, Limburg PC, Kallenberg CG, Bijl M. Type I interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythaematosus patients. Ann. Rheum. Dis. 67(1), 11-18 (2008).
31. Wang GS, Zhang M, Li XP et al. Ultraviolet B exposure of peripheral blood mononuclear cells of patients with systemic lupus erythematosus inhibits DNA methylation. Lupus 18(12), 1037-1044 (2009).
32. Kazazian HH Jr. Genetics. L1 retrotransposons shape the mammalian genome. Science 289(5482), 1152-1153 (2000).
33. Blank M, Shoenfeld Y, Perl A. Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. Lupus 18(13), 1136-1143 (2009).
34. Yoshiki T, Mellors RC, Strand M, August JT. The viral envelope glycoprotein of murine leukemia virus and the pathogenesis of immune complex glomerulonephritis of New Zealand mice. J. Exp. Med. 140(4), 1011-1027 (1974).
35. Izui S, McConahey PJ, Theofilopoulos AN, Dixon FJ. Association of circulating retroviral gp70-anti-gp70 immune complexes with murine systemic lupus erythematosus. J. Exp. Med. 149(5), 1099-1116 (1979).
36. Shirai T, Ohta K, Kohno A et al. Naturally occurring antibody response to DNA is associated with the response to retroviral gp70 in autoimmune New Zealand mice. Arthritis Rheum. 29(2), 242-250 (1986).
37. Banki K, Maceda J, Hurley E et al. Human T-cell lymphotropic virus (HTLV)-related endogenous sequence, HRES-1, encodes a 28-kDa protein: A possible autoantigen for HTLV-I gag-reactive autoantibodies. Proc. Natl Acad. Sci. USA 89(5), 1939-1943 (1992).
38. Herrmann M, Hagenhofer M, Kalden JR. Retroviruses and systemic lupus erythematosus. Immunol. Rev. 152, 145-156 (1996).
39. Nakagawa K, Harrison LC. The potential roles of endogenous retroviruses in autoimmunity. Immunol. Rev. 152, 193-236 (1996).
40. Brookes SM, Pandolfino YA, Mitchell TJ et al. The immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease. Br. J. Rheumatol. 31(11), 735-742 (1992).
41. Blomberg J, Nived O, Pipkorn R, Bengtsson A, Erlinge D, Sturfelt G. Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus. Correlation with autoantibodies and clinical manifestations. Arthritis Rheum. 37(1), 57-66 (1994).
42. Herrmann M, Kalden JR. PCR and reverse dot hybridization for the detection of endogenous retroviral transcripts. J. Virol. Methods 46(3), 333-348 (1994).
43. Mellors RC, Mellors JW. Antigen related to mammalian type-C RNA viral p30 proteins is located in renal glomeruli in human systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 73(1), 233-237 (1976).
44. Reynolds JT, Panem S. Characterization of antibody to C-type virus antigens isolated from immune complexes in kidneys of patients with systemic lupus erythematosus. Lab. Invest. 44(5), 410-419 (1981).
45. Ogasawara H, Naito T, Kaneko H et al. Quantitative analyses of messenger RNA of human endogenous retrovirus in patients with systemic lupus erythematosus. J. Rheumatol. 28(3), 533-538 (2001).
46. Rich SA. Human lupus inclusions and interferon. Science 213(4509), 772-775 (1981).
47. Haraguchi S, Good RA, Cianciolo GJ, Engelman RW, Day NK. Immunosuppressive retroviral peptides: Immunopathological implications for immunosuppressive influences of retroviral infections. J. Leukoc. Biol. 61(6), 654-666 (1997).
48. Kaneko H, Yamada H, Mizuno S et al. Role of tumor necrosis factor-a in Mycobacterium-induced granuloma formation in tumor necrosis factor-a-deficient mice. Lab. Invest. 79(4), 379-386 (1999).
49. Mellors RC, Mellors JW. Type C RNA virus-specific antibody in human systemic lupus erythematosus demonstrated by enzymoimmunoassay. Proc. Natl Acad. Sci. USA 75(5), 2463-2467 (1978).
50. Sabbatini A, Bombardieri S, Migliorini P. Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I. Eur. J. Immunol. 23(5), 1146-1152 (1993).
51. Ogasawara H, Hishikawa T, Sekigawa I, Hashimoto H, Yamamoto N, Maruyama N. Sequence analysis of human endogenous retrovirus clone 4-1 in systemic lupus erythematosus. Autoimmunity 33(1), 15-21 (2000).
52. Li Y, Liu Y, Strickland FM, Richardson B. Age-dependent decreases in DNA methyltransferase levels and low transmethylation micronutrient levels synergize to promote overexpression of genes implicated in autoimmunity and acute coronary syndromes. Exp. Gerontol. 45(4), 312-322 (2010).
53. Liu C, Ou T, Wu C et al. Global DNA methylation, DNMT1, and MBD2 in patients with systemic lupus erythematosus. Lupus 20(2), 131-136 (2011).
54. Franceschi C, Bonafe M, Valensin S et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. NY Acad. Sci. 908, 244-254 (2000).
55. Nilsson BO, Skogh T, Ernerudh J et al. Antinuclear antibodies in the oldest-old women and men. J. Autoimmun. 27(4), 281-288 (2006).
56. Yung RL, Julius A. Epigenetics, aging, and autoimmunity. Autoimmunity 41(4), 329-335 (2008).
57. Agrawal A, Tay J, Yang G-E, Agrawal S, Gupta S. Age-associated epigenetic modifications in human DNA increase its immunogenicity. Aging 2(2), 93-100 (2010).
58. Fraga MF, Ballestar E, Paz MF et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad. Sci. USA 102(30), 10604-10609 (2005).
59. Kaplan MJ, Beretta L, Yung RL, Richardson BC. LFA-1 overexpression and T cell autoreactivity: Mechanisms. Immunol. Invest. 29(4), 427-442 (2000).
60. Hawkins HK, Heffelfinger SC, Anderson DC. Leukocyte adhesion deficiency: Clinical and postmortem observations. Pediatr. Pathol. 12(1), 119-130 (1992).
61. Takeuchi T, Amano K, Sekine H, Koide J, Abe T. Upregulated expression and function of integrin adhesive receptors in systemic lupus erythematosus patients with vasculitis. J. Clin. Invest. 92(6), 3008-3016 (1993).
62. Lu Q, Kaplan M, Ray D, Zacharek S, Gutsch D, Richardson B. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum. 46(5), 1282-1291 (2002).
63. Yung R, Powers D, Johnson K et al. Mechanisms of drug-induced lupus II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J. Clin. Invest. 97(12), 2866-2871 (1996).
64. Sawalha AH, Jeffries M, Webb R et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun. 9(4), 368-378 (2008).
65. Callard RE, Armitage RJ, Fanslow WC, Spriggs MK. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol. Today 14(11), 559-564 (1993).
66. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci. 58(1), 4-43 (2001).
67. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 108(16), 1917-1923 (2003).
68. Ciferska H, Horak P, Hermanova Z et al. The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin. Rheumatol. 26(5), 723-728 (2007).
69. Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J. Autoimmun. 26(3), 165-171 (2006).
70. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154(3), 1470-1480 (1995).
71. Fernandez-Gutierrez B, de Miguel S, Morado C, Hernandez-Garcia C, Banares A, Jover JA. Defective early T and T-dependent B cell activation in systemic lupus erythematosus. Lupus 7(5), 314-322 (1998).
72. Lettesjo H, Burd GP, Mageed RA. CD4+ T lymphocytes with constitutive CD40 ligand in preautoimmune (NZB x NZW)F1 lupus-prone mice: Phenotype and possible role in autoreactivity. J. Immunol. 165(7), 4095-4104 (2000).
73. Zhou Y, Yuan J, Pan Y et al. T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clin. Immunol. 132(3), 362-370 (2009).
74. Lu Q, Wu A, Tesmer L, Ray D, Yousif N, Richardson B. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J. Immunol. 179(9), 6352-6358 (2007).
75. Sugita K, Torimoto Y, Nojima Y, Daley JF, Schlossman SF, Morimoto C. The 1A4 molecule (CD27) is involved in T cell activation. J. Immunol. 147(5), 1477-1483 (1991).
76. Oelke K, Lu Q, Richardson D et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum. 50(6), 1850-1860 (2004).
77. Hintzen RQ, Lens SM, Lammers K, Kuiper H, Beckmann MP, van Lier RA. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J. Immunol. 154(6), 2612-2623 (1995).
78. Brown GR, Meek K, Nishioka Y, Thiele DL. CD27-CD27 ligand/CD70 interactions enhance alloantigen-induced proliferation and cytolytic activity in CD8+ T lymphocytes. J. Immunol. 154(8), 3686-3695 (1995).
79. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1(5), 433-440 (2000).
80. Oelke K, Lu Q, Richardson D et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum. 50(6), 1850-1860 (2004).
81. Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J. Immunol. 174(10), 6212-6219 (2005).
82. Yin H, Zhao M, Wu X et al. Hypomethylation and overexpression of CD70 (TNFSF7) in CD4+ T cells of patients with primary Sjogren's syndrome. J. Dermatol. Sci. 59(3), 198-203 (2010).
83. Luo Y, Zhao M, Lu Q. Demethylation of promoter regulatory elements contributes to CD70 overexpression in CD4+ T cells from patients with subacute cutaneous lupus erythematosus. Clin. Exp. Dermatol. 35(4), 425-430 (2010).
84. Lee WW, Yang ZZ, Li G, Weyand CM, Goronzy JJ. Unchecked CD70 expression on T cells lowers threshold for T cell activation in rheumatoid arthritis. J. Immunol. 179(4), 2609-2615 (2007).
85. Weyand CM, Brandes JC, Schmidt D, Fulbright JW, Goronzy JJ. Functional properties of CD4+ CD28- T cells in the aging immune system. Mech. Ageing Dev. 102(2-3), 131-147 (1998).
86. van Bergen J, Koning F. The tortoise and the hare: Slowly evolving T-cell responses take hastily evolving KIR. Immunology 131(3), 301-309 (2010).
87. Nakajima T, Schulte S, Warrington KJ et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 105(5), 570-575 (2002).
88. Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH. Structure and function of natural killer cell receptors: Multiple molecular solutions to self, nonself discrimination. Annu. Rev. Immunol. 20, 853-885 (2002).
89. Basu D, Liu Y, Wu A et al. Stimulatory and inhibitory killer Ig-like receptor molecules are expressed and functional on lupus T cells. J. Immunol. 183(5), 3481-3487 (2009).
90. Valiante NM, Uhrberg M, Shilling HG et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7(6), 739-751 (1997).
91. Liu Y, Kuick R, Hanash S, Richardson B. DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin. Immunol. 130(2), 213-224 (2009).
92. Kikuchi-Maki A, Yusa S, Catina TL, Campbell KS. KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J. Immunol. 171(7), 3415-3425 (2003).
93. Young JD, Hengartner H, Podack ER, Cohn ZA. Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer activity. Cell 44(6), 849-859 (1986).
94. Appay V, Zaunders JJ, Papagno L et al. Characterization of CD4(+) CTLs ex vivo. J. Immunol. 168(11), 5954-5958 (2002).
95. Kaplan MJ, Lu Q, Wu A, Attwood J, Richardson B. Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J. Immunol. 172(6), 3652-3661 (2004).
96. Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 52(1), 201-211 (2005).
97. Kozlowska A, Hrycaj P, Lacki JK, Jagodzinski PP. Perforin level in CD4+ T cells from patients with systemic lupus erythematosus. Rheumatol. Int. 30(12), 1627-1633 (2010).
98. Luo Y, Zhang X, Zhao M, Lu Q. DNA demethylation of the perforin promoter in CD4(+) T cells from patients with subacute cutaneous lupus erythematosus. J. Dermatol. Sci. 56(1), 33-36 (2009).
99. Mohan C, Morel L, Yang P, Wakeland EK. Accumulation of splenic B1a cells with potent antigen-presenting capability in NZM2410 lupus-prone mice. Arthritis Rheum. 41(9), 1652-1662 (1998).
100. Piatelli MJ, Tanguay D, Rothstein TL, Chiles TC. Cell cycle control mechanisms in B-1 and B-2 lymphoid subsets. Immunol. Res. 27(1), 31-52 (2003).
101. Renaudineau Y, Hillion S, Saraux A, Mageed RA, Youinou P. An alternative exon 1 of the CD5 gene regulates CD5 expression in human B lymphocytes. Blood 106(8), 2781-2789 (2005).
102. Renaudineau Y, Vallet S, Le Dantec C, Hillion S, Saraux A, Youinou P. Characterization of the human CD5 endogenous retrovirus-E in B lymphocytes. Genes Immun. 6(8), 663-671 (2005).
103. Garaud S, Le Dantec C, Berthou C, Lydyard PM, Youinou P, Renaudineau Y. Selection of the alternative exon 1 from the cd5 gene down-regulates membrane level of the protein in B lymphocytes. J. Immunol. 181(3), 2010-2018 (2008).
104. Garaud S, Le Dantec C, Jousse-Joulin S et al. IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J. Immunol. 182(9), 5623-5632 (2009).
105. Jeffries M, Dozmorov M, Tang Y, Merrill JT, Wren JD, Sawalha AH. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics 6(5) 593-601 (2011).
106. Yoshihara Y, Nakamura H, Obata K et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann. Rheum. Dis. 59(6), 455-461. (2000).
107. Perez P, Goicovich E, Alliende C et al. Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum. 43(12), 2807-2817 (2000).
108. Kurasawa K, Arai S, Owada T, Maezawa R, Kumano K, Fukuda T. Autoantibodies against platelet-derived growth factor receptor alpha in patients with systemic lupus erythematosus. Mod. Rheumatol. 20(5), 458-465 (2010).
109. Tai XG, Yashiro Y, Abe R et al. A role for CD9 molecules in T cell activation. J. Exp. Med. 184(2), 753-758 (1996).
110. Kuhl BD, Sloan RD, Donahue DA, Bar-Magen T, Liang C, Wainberg MA. Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology 7, 115 (2010).
111. Fainaru O, Woolf E, Lotem J et al. Runx3 regulates mouse TGF-beta-mediated dendritic cell function and its absence results in airway inflammation. EMBO J. 23(4), 969-979 (2004).
112. Dominguez-Soto A, Relloso M, Vega MA, Corbi AL, Puig-Kroger A. RUNX3 regulates the activity of the CD11a and CD49d integrin gene promoters. Immunobiology 210(2-4), 133-139 (2005).
113. Zhao M, Sun Y, Gao F et al. Epigenetics and SLE: RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4+ T cells. J. Autoimmun. 35(1), 58-69 (2010).
114. Zhao M, Wu X, Zhang Q et al. RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1. Arthritis Res. Ther. 12(6), R227 (2010).
115. Dieker J, Muller S. Epigenetic histone code and autoimmunity. Clin. Rev. Allergy Immunol. 39(1), 78-84 (2010).
116. Garcia BA, Busby SA, Shabanowitz J, Hunt DF, Mishra N. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J. Proteome Res. 4(6), 2032-2042 (2005).
117. Murr R, Loizou JI, Yang YG et al. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat. Cell Biol. 8(1), 91-99 (2006).
118. Huggins ML, Todd I, Cavers MA, Pavuluri SR, Tighe PJ, Powell RJ. Antibodies from systemic lupus erythematosus (SLE) sera define differential release of autoantigens from cell lines undergoing apoptosis. Clin. Exp. Immunol.118(2), 322-328 (1999).
119. van Bavel CC, Dieker J, Muller S et al. Apoptosis-associated acetylation on histone H2B is an epitope for lupus autoantibodies. Mol. Immunol. 47(2-3), 511-516 (2009).
120. Dieker JW, Fransen JH, van Bavel CC et al. Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum. 56(6), 1921-1933 (2007).
121. Batova I, Kowal C, May R, Scharff MD, Diamond B. Human recombinant Fab fragments with sub-nanomolar affinities for acetylated histones. J. Immunol. Methods 329(1-2), 1-10 (2008).
122. Plaue S, Muller S, van Regenmortel MH. A branched, synthetic octapeptide of ubiquitinated histone H2A as target of autoantibodies. J. Exp. Med. 169(5), 1607-1617 (1989).
123. Muller S, Briand JP, Van Regenmortel MH. Presence of antibodies to ubiquitin during the autoimmune response associated with systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 85(21), 8176-8180 (1988).
124. Stockl F, Muller S, Batsford S et al. A role for histones and ubiquitin in lupus nephritis? Clin. Nephrol. 41(1), 10-17 (1994).
125. Zhang Z, Song L, Maurer K, Petri MA, Sullivan KE. Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes. Genes Immun. 11(2), 124-133 (2010).
126. Williams AE. Functional aspects of animal microRNAs. Cell. Mol. Life Sci. 65(4), 545-562 (2008).
127. Fabbri M, Garzon R, Cimmino A et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl Acad. Sci. USA 104(40), 15805-15810 (2007).
128. Garzon R, Heaphy CE, Havelange V et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 114(26), 5331-5341 (2009).
129. Dai R, Zhang Y, Khan D et al. Identification of a common lupus disease-associated microRNA Expression pattern in three different murine models of lupus. PloS ONE 5(12), e14302 (2010).
130. Pan W, Zhu S, Yuan M et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J. Immunol. 184(12), 6773-6781 (2010).
131. Zhao S, Wang Y, Liang Y, Zhao M, Long H, Ding S, et al. MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum. 63(5), 1376-1386 (2011).
132. Berger JR, Houff SA, Major EO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs. 1(6), 583-589 (2009).
133. Griffiths EA, Gore SD, Hooker C et al. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk. Lymphoma 51(9), 1711-1719 (2010).
134. Roman-Gomez J, Jimenez-Velasco A, Barrios M et al. Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes. Leuk. Lymphoma 48(7), 1269-1282 (2007).
135. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA et al. Promoter hypermethylation of cancer-related genes: A strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104(8), 2492-2498 (2004).
136. Ikeda Y, Kinoshita T. DNA demethylation: A lesson from the garden. Chromosoma 118(1), 37-41 (2009).
137. Zhu J-K. Active DNA Demethylation mediated by DNA glycosylases. Ann. Rev. Genetics 43, 143-166 (2009).
138. Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 135(7), 1201-1212 (2008).
139. Shuttleworth SJ, Bailey SG, Townsend PA. Histone deacetylase inhibitors: New promise in the treatment of immune and inflammatory diseases. Curr. Drug Targets 11(11), 1430-1438 (2010).
140. Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137(6), 1338-1344 (2010).
141. Barnes PJ. Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 6(8), 693-696 (2009).
142. Cosio BG, Iglesias A, Rios A et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax 64(5), 424-429 (2009).
143. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu. Rev. Physiol. 71, 451-464 (2009).
144. Marwick JA, Ito K, Adcock IM, Kirkham PA. Oxidative stress and steroid resistance in asthma and COPD: Pharmacological manipulation of HDAC-2 as a therapeutic strategy. Expert Opin. Ther. Targets 11(6), 745-755 (2007).